Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Merck
Baxter
Express Scripts
Colorcon

Last Updated: December 11, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TAFAMIDIS MEGLUMINE

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

All Clinical Trials for Tafamidis Meglumine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01435655 The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin Completed Pfizer Phase 3 2011-11-01 Tafamidis has been developed as an oral specific stabilizer of transthyretin tetramer.
NCT01994889 Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy Active, not recruiting Pfizer Phase 3 2013-12-01 This Phase 3 study will investigate the efficacy, safety and tolerability of an oral daily dose of 20 mg or 80 mg tafamidis meglumine capsules compared to placebo in subjects with either transthyretin genetic variants or wild-type transthyretin resulting in amyloid cardiomyopathy.
NCT02791230 Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy Recruiting Pfizer Phase 3 2016-06-01 Phase 3 extension study to evaluate the safety of oral daily dosing of 20 mg or 80 mg tafamidis meglumine in subjects with either transthyretin genetic variants or wild-type transthyretin resulting in amyloid cardiomyopathy
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tafamidis Meglumine

Condition Name

Condition Name for Tafamidis Meglumine
Intervention Trials
Transthyretin (TTR) Amyloid Cardiomyopathy 2
Healthy 2
Transthyretin Familial Amyloid Polyneuropathy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Tafamidis Meglumine
Intervention Trials
Amyloidosis 3
Cardiomyopathies 2
Amyloid Neuropathies 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Tafamidis Meglumine

Trials by Country

Trials by Country for Tafamidis Meglumine
Location Trials
United States 30
Japan 4
Belgium 4
Spain 3
Canada 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Tafamidis Meglumine
Location Trials
Alabama 2
New York 2
Minnesota 2
Michigan 2
Maryland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Tafamidis Meglumine

Clinical Trial Phase

Clinical Trial Phase for Tafamidis Meglumine
Clinical Trial Phase Trials
Phase 3 3
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Tafamidis Meglumine
Clinical Trial Phase Trials
Recruiting 2
Not yet recruiting 2
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Tafamidis Meglumine

Sponsor Name

Sponsor Name for Tafamidis Meglumine
Sponsor Trials
Pfizer 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Tafamidis Meglumine
Sponsor Trials
Industry 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Mallinckrodt
Colorcon
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.